The Supreme Court case that could slow generic drugs
It’s a case you’ve (probably) never heard of: This week, the Supreme Court is hearing oral arguments in Hikma v. Amarin — a legal battle that could impact how much you ultimately pay for prescription drugs.
Here’s why the case matters: As soon as a generic version of a brand-name drug comes to market, its price typically drops by half. Within 10 years, by more than 75%. Meaning: the sooner we have access to generics, the less we pay at the pharmacy counter.
But one of the fastest legal pathways for generic companies to get their drugs to market may be about to get a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.